62 search results for: coexisting diseases

At the 2026 EADV Congress, Prof. Tilo Biedermann and Drs. Nicole Chase and Lisa Swanson present a holistic view of atopic dermatitis (AD) management from childhood to adulthood centered around type 2 inflammation. Beginning with the hypothesis that reduced exposure to helminths in increasingly industrialized societies may have diminished natural immunomodulatory mechanisms, they explore how dysregulated type 2 inflammation can manifest as AD and extend beyond the skin. The discussion then focuses on adults with uncontrolled AD, highlighting the multidimensional, cumulative burden of disease across the lifespan—and how targeted systemic therapy may help achieve sustained disease control. Finally, the faculty explore pediatric AD as a critical window for early intervention, with the potential to alter disease progression and prevent comorbidities.

Prof. Tilo Biedermann discusses the key roles of type 2 cytokines IL-4, IL-13, and IL-31 in the pathophysiology of atopic dermatitis. He then describes how these cytokines can be targeted with systemic therapies to elicit long-term disease control and reduce the burden of atopic and non-atopic comorbidities, which are meaningful outcomes for patients with uncontrolled disease.